文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Identification and validation of glycosyltransferase-related gene signatures to predict prognosis and immunological characteristics of renal clear cell carcinoma.

作者信息

Ma Min, Huang Ting, Xu Zekun, Xu Min

机构信息

Department of Urology, Jinhua Municipal Central Hospital, Jinhua, China.

出版信息

Transl Androl Urol. 2025 Apr 30;14(4):986-1004. doi: 10.21037/tau-2025-21. Epub 2025 Apr 27.


DOI:10.21037/tau-2025-21
PMID:40376527
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12076249/
Abstract

BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is more prone to metastasis and is associated with a poorer prognosis than renal cell carcinoma (RCC). Numerous studies have reported a correlation between the expression of glycosyltransferases (GTs)-related genes and tumor. We aimed to establish a risk model based on GTs-related genes in ccRCC, and explore their correlation with tumor immune characteristics and treatment sensitivity. METHODS: The messenger ribonucleic acid (mRNA) expression data were retrieved from The Cancer Genome Atlas (TCGA). Univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression were used to construct prognostic model. Kaplan-Meier survival and receiver operating characteristic (ROC) curves were used to evaluate the accuracy of the model. Calibration curves and decision curve analysis (DCA) curves were used to evaluate the model. The quantitative real-time polymerase chain reaction (qRT-PCR) was applied to detect the expression of the signature genes in human renal epithelial cells and human renal cancer cells. The ESTIMATE algorithm was used to estimate the immune scores in tumor tissues. Single-sample gene set enrichment analysis (ssGSEA) was used to evaluate the immune microenvironment. Tumor Immune Dysfunction and Exclusion (TIDE) and immune checkpoint analysis were used to assess the benefit of immunotherapy. Tumor mutational burden (TMB) analysis was used to calculate the frequency of gene mutations. Susceptibility to anticancer drugs in different risk groups was also analyzed. RESULTS: Four signature genes were identified as potential biomarkers, and the prognostic model demonstrated good predictive performance. qRT-PCR results were consistent with the actual predictions, confirming the credibility of the signature genes. The high- and low-risk groups exhibited different abundance and enrichment of immune cell infiltration. The high-risk group exhibited a higher frequency of tumor mutations than the low-risk group. TIDE and drug sensitivity analysis results demonstrated appropriate treatments for different risk groups, respectively. CONCLUSIONS: A prognostic model for ccRCC with four signature genes, was established and demonstrated high predictive performance. Four signature genes provided a foundation for studying the mechanism of GTs-related genes in ccRCC progression.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/bc8d8c03cba4/tau-14-04-986-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/aa986bec84a5/tau-14-04-986-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/2b6450c7012d/tau-14-04-986-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/08686f18f64c/tau-14-04-986-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/6b350e300630/tau-14-04-986-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/6a436b5496e3/tau-14-04-986-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/5d0645c9f0d2/tau-14-04-986-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/326bfa9a1304/tau-14-04-986-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/22d7d4f22a37/tau-14-04-986-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/bc8d8c03cba4/tau-14-04-986-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/aa986bec84a5/tau-14-04-986-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/2b6450c7012d/tau-14-04-986-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/08686f18f64c/tau-14-04-986-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/6b350e300630/tau-14-04-986-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/6a436b5496e3/tau-14-04-986-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/5d0645c9f0d2/tau-14-04-986-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/326bfa9a1304/tau-14-04-986-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/22d7d4f22a37/tau-14-04-986-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3c9/12076249/bc8d8c03cba4/tau-14-04-986-f9.jpg

相似文献

[1]
Identification and validation of glycosyltransferase-related gene signatures to predict prognosis and immunological characteristics of renal clear cell carcinoma.

Transl Androl Urol. 2025-4-30

[2]
Identification of ferroptosis-related gene signatures as a novel prognostic model for clear cell renal cell carcinoma.

Discov Oncol. 2025-4-3

[3]
Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma.

Transl Androl Urol. 2023-4-28

[4]
Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.

J Cancer Res Clin Oncol. 2023-12

[5]
Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.

Front Cell Dev Biol. 2022-8-23

[6]
Identification and verification of a novel anoikis-related gene signature with prognostic significance in clear cell renal cell carcinoma.

J Cancer Res Clin Oncol. 2023-10

[7]
Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.

Sci Rep. 2024-1-5

[8]
Identification and validation of a gap junction protein related signature for predicting the prognosis of renal clear cell carcinoma.

Front Oncol. 2024-2-22

[9]
Development and validation of a combined hypoxia- and metabolism-related prognostic signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma.

Front Oncol. 2023-11-10

[10]
Comprehensive analysis of LD-related genes signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.

BMC Nephrol. 2024-9-10

本文引用的文献

[1]
Global burden, trends, and disparities in kidney cancer attributable to smoking from 1990 to 2021.

Front Public Health. 2025-1-8

[2]
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma.

Cancer Treat Rev. 2025-2

[3]
Prognostic Value of Neutrophil-to-Eosinophil Ratio (NER) in Cancer: A Systematic Review and Meta-Analysis.

Cancers (Basel). 2024-10-31

[4]
METTL3-mediated TIM1 promotes macrophage M1 polarization and inflammation through IGF2BP2-dependent manner.

J Biochem Mol Toxicol. 2024-10

[5]
Exploring the common mechanisms and biomarker ST8SIA4 of atherosclerosis and ankylosing spondylitis through bioinformatics analysis and machine learning.

Front Cardiovasc Med. 2024-7-18

[6]
Glycosylation: mechanisms, biological functions and clinical implications.

Signal Transduct Target Ther. 2024-8-5

[7]
Diffuse tumors: Molecular determinants shared by different cancer types.

Comput Biol Med. 2024-8

[8]
Diagnostic, predictive and prognostic molecular biomarkers in clear cell renal cell carcinoma: A retrospective study.

Cancer Rep (Hoboken). 2024-6

[9]
Multiaction Pt(IV) Prodrugs Releasing Cisplatin and Dasatinib Are Potent Anticancer and Anti-Invasive Agents Displaying Synergism between the Two Drugs.

J Med Chem. 2024-6-13

[10]
Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis.

Cancers (Basel). 2024-5-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索